01.002 RWE GS May 2022 C 10-05-2022

Largest long COVID real-world evidence study (STIMULATE-ICP) approved in the UK

“Two million people in the UK are estimated to have had persistent symptoms for more than 12 weeks following initial COVID infection, with far-reaching impact on patients, healthcare and the economy. More than 80 long COVID clinics have been established around England but we need to better understand, diagnose and treat this new disease. Inequalities in access to and provision of long COVID care have already become apparent. Long COVID is challenging the NHS and healthcare systems around the world, which have had to deal with the acute consequences of coronavirus over the last 18 months,”                                                                            Professor Amitava Banerjee, Chief Investigator STIMULATE-ICP Click here to learn more.

About SVMPharma

SVMPharma is an innovative strategic consultancy and CRO, with a focus in Real World Evidence (RWE) for pharmaceutical and biotechnology companies. SVMPharma delivers clinical trials within UK and Europe.


DISTILL is a new EDC launched by SVMPharma. As a CRO discover the benefits of DISTILL as part of your service offering and take back control of your clinical trials. DISTILL allows you to develop and manage every aspect of your trials from start to finish. Move away from the restrictions and costs associated with legacy systems.

For more information, please visit and contact us at